A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients

• Status: Recruiting
• Trial end date: 2024-12-31

Summary

1. To explore the functional changes of P-gp, CYP3A4, OATP1B and BCRP in Chinese people with renal impairment;

2. To explore the effect of dialysis on the functional changes of P-gp, CYP3A4, OATP1B and BCRP in patients with end-stage renal disease;

3. Validation of urotoxic molecules as possible biomarkers that can assess intestinal P-gp function.

• Phase: Phase 4

Details

• Lead Sponsor: Peking University Third Hospital
• Treatments: Atorvastatin; Dabigatran; Midazolam; Pitavastatin; Rosuvastatin Calcium